Rare Disease Stakeholders Demand Regulatory Clarity

Rare Disease Stakeholders Demand Regulatory Clarity

The Food and Drug Administration (FDA) asked for rare disease stakeholders, including individuals and families affected by rare disease(s), pharmaceutical companies, trade associations, and other federal agencies and regulators, to weigh in on a proposed clinical...